• 나누는사람들
• /
• 통권30호
• /
• pp.4-7
• /
• 2005

• Clinical and Experimental Pediatrics
• /
• 제49권9호
• /
• pp.987-990
• /
• 2006

정맥내 면역글로블린은 급성 가와사끼병의 치료에 효과적이나 약 10-20%의 환자에서 치료 실패가 보고되고 있다. 이러한 경우 면역글로블린의 재투여 또는 스테로이드나 다른 약제의 사용 등 다양한 치료방법이 시도되고 있으나 아직 이에 대한 확립된 치료 가이드라인은 없다. $TNF-{\alpha}$는 가와사끼병의 급성기, 특히 관상동맥류를 가진 환자에서 혈중농도가 크게 증가한다. 저자들은 2번의 면역글로블린 투여와 3번의 pulse methylprednisolone 치료에 반응이 없던 10개월 된 난치성 가와사끼병 환아에게 항 $TNF-{\alpha}$인 infliximab (5 mg/kg, 1회)을 투여하여 임상 호전과 더불어 항염증지표가 정상이 되고 관상동맥류 진행이 억제됨을 경험하였다.

• Clinical and Experimental Reproductive Medicine
• /
• 제32권2호
• /
• pp.165-170
• /
• 2005

Objective: The aim of present study was to evaluate the effectiveness of low-dose intravenous immunoglobulin (IVIg) therapy in women with recurrent spontaneous abortions (RSA) and elevated pre-conceptional peripheral blood CD56+Natural Killer (NK) cell percentage. Study Design: Retrospective case control study. Materials and Methods: Thirty three women with RSA and elevated pre-conceptional peripheral blood CD56+NK cell percentage who had received low-dose IVIg therapy (400 mg/kg per day, every 4 week, until 20 gestational weeks) were included in this study. Controls were nine women with RSA and elevated pre-conceptional peripheral blood CD56+ Natural Killer (NK) cell percentage who had not received IVIg therapy were included in this study. Medical records of study and control groups were retrospectively analyzed and we compared the successful pregnancy outcomes between two groups. Successful pregnancy outcome was defined as pregnancy ongoing beyond 25 gestational weeks. Results: Age, number of previous abortions, pre-conceptional CD56+NK cell percentage and type of RSA were not statistically different between two groups. Otherwise, twenty-five women who received IVIg therapy (25/33, 75.8%) but, only three women who had not received (3/9, 33.3%) had a successful pregnancy outcome and the rate difference between two groups was statistically significant. Conclusion: Based on our study, low-dose IVIg therapy have a effective role in treatment of RSA patients with elevated pre-conceptional peripheral blood CD56+ Natural Killer (NK) cell percentage, but more larger scaled prospective study is needed for available of conclusive evidence.